Clinical trials: Lung Cancer Non-Small Cell Cancer (NSCLC)
NSCLC, Recurrent, Adenocarcinoma of Lung
Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma
A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA
- Trial name
- N3 (NCT03361319)
- Testing
- Vargatef, Abraxane
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-small Cell Lung Cancer
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.
- Trial name
- NCT06634667
- Testing
- third-generation EGFR-TKI combined with anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer (NSCLC)
A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients
This is a prospective, randomized, multicenter clinical study designed to evaluate its safety and efficacy by using Docetaxel with or without Traditional Chinese Medicine XH1 in patients with Stage ⅢB-Ⅳ Non-small Cell Lung Cancer…
- Trial name
- NCT03407300
- Testing
- Docetaxel, Chinese traditional medicine XH1
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Haining Health-Coming Biotech Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
This study will evaluate the efficacy and safety of alectinib, in selected participants, with anaplastic lymphoma kinase-rearranged (ALK-rearranged) non-small cell lung cancer (NSCLC), after disease progression on prior treatment…
- Trial name
- ATALK (NCT03155009)
- Testing
- Alectinib
- Where
- 16 sites in France
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Resectable Locally Advanced Non-small Cell Lung Cancer
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
This is a multicenter, randomized, open label, phase II study.
- Trial name
- ALTER-L043 (NCT04846634)
- Testing
- Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer Metastatic
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
- Trial name
- DEEP-Lung-IV (NCT04994795)
- Testing
- Predictive models (data collection)
- Where
- 30 sites in United States, Brazil and 6 more
- Volunteers
- 4,000 people
- Sponsor
- Sophia Genetics SAS
Non-Small Cell Lung Cancer
Marker Guided Breathhold Radiotherapy in NSCLC
Proof of concept study evaluating safety and performance of a gel marker (BioXmark) used for image guidance in deep inspiration breathhold radiotherapy (DIBH IGRT) in patients with locally advanced non-small cell lung cancer…
- Trial name
- NCT02447900
- Testing
- BioXmark
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Steen Riisgaard Mortensen
Non-small Cell Lung Cancer
A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer
A study to compare patient survivals in the N2 patients with non-small cell lung cancer in the subgroups of lymph skip metastases and non-skip metastases
- Trial name
- NCT03429192
- Testing
- Surgery
- Where
- 9 sites in China
- Volunteers
- 2,653 people
- Sponsor
- Tianjin Chest Hospital
Colorectal Cancer
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus…
- Trial name
- M13DAP (NCT02039336)
- Testing
- Dacomitinib, PD-0325901, Docetaxel
- Where
- 3 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage I
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
- Trial name
- STILE (NCT03383302)
- Testing
- Stereotactic body radiotherapy, Nivolumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
This clinical Trial is proposed to explore whether preconditioning chemotherapy of Paclitaxel+cisplatin(TP)regimen combined with autologous adoptive CIK cell immunotherapy could benefit NSCLC patients with a better clinical…
- Trial name
- NCT01902875
- Testing
- Paclitaxel + Cisplatin, CIK cell therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinling Hospital, China
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Lung Cancer, Non-Small Cell
A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
This study is a phase Ib, single-center, single-arm exploratory clinical study designed to evaluate the safety and efficacy of Golidocitinib in combination with anti-PD-1 monoclonal antibody in locally advanced or metastatic…
- Trial name
- NCT06690671
- Testing
- Golidocitinib in combination with anti-PD-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary…
- Trial name
- REVEAL (NCT04836975)
- Where
- Saudi Arabia
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Advanced Non-small Cell Lung Cancer
Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as…
- Trial name
- NCT03334864
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer Stage IV
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for…
- Trial name
- NCT05055167
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Lung Cancer
Paclitaxel in Treating Patients With Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have unresectable…
- Trial name
- NCT00002972
- Testing
- paclitaxel
- Where
- 5 sites in Belgium, Czechia and 3 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer, Metastatic Cancer
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC.
- Trial name
- NCT01514877
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.